DD154608A5 - Verfahren zur herstellung von 1x oxo-1h-thiazolo-[3,2-a]pyrimidin-carboxamiden u.deren zwischenstufen - Google Patents

Verfahren zur herstellung von 1x oxo-1h-thiazolo-[3,2-a]pyrimidin-carboxamiden u.deren zwischenstufen Download PDF

Info

Publication number: DD154608A5
Authority: DD; German Democratic Republic
Prior art keywords: oxo; pyrimidine; ethyl; compound; mmol
Prior art date: 1979-11-23

Application number

DD80225391A

Other languages

German (de)

English (en)

Inventor

Saul B Kadin

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1979-11-23

Filing date

1980-11-21

Publication date

1982-04-07

1980-11-21 Application filed by Pfizer filed Critical Pfizer

1982-04-07 Publication of DD154608A5 publication Critical patent/DD154608A5/de

Links

238000000034 method Methods 0.000 title claims abstract description 36
230000008569 process Effects 0.000 title claims abstract description 11
238000002360 preparation method Methods 0.000 title claims abstract description 6
150000001875 compounds Chemical class 0.000 claims abstract description 61
125000004432 carbon atom Chemical group C* 0.000 claims abstract description 19
125000000217 alkyl group Chemical group 0.000 claims abstract description 14
125000002947 alkylene group Chemical group 0.000 claims abstract description 6
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 47
238000010438 heat treatment Methods 0.000 claims description 29
ULRPISSMEBPJLN-UHFFFAOYSA-N 2h-tetrazol-5-amine Chemical compound NC1=NN=NN1 ULRPISSMEBPJLN-UHFFFAOYSA-N 0.000 claims description 28
QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 claims description 22
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims description 20
239000001257 hydrogen Substances 0.000 claims description 15
229910052739 hydrogen Inorganic materials 0.000 claims description 15
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
101000588924 Anthopleura elegantissima Delta-actitoxin-Ael1a Proteins 0.000 claims description 11
239000003960 organic solvent Substances 0.000 claims description 9
239000003085 diluting agent Substances 0.000 claims description 8
238000009835 boiling Methods 0.000 claims description 5
125000004122 cyclic group Chemical group 0.000 claims description 5
239000007788 liquid Substances 0.000 claims description 5
239000007822 coupling agent Substances 0.000 claims description 4
150000003512 tertiary amines Chemical class 0.000 claims description 4
125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 claims description 4
230000009471 action Effects 0.000 claims description 3
239000011260 aqueous acid Substances 0.000 claims description 3
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 2
229910052799 carbon Inorganic materials 0.000 claims description 2
FUXJMHXHGDAHPD-UHFFFAOYSA-N pyrimidine-2-carboxamide Chemical class NC(=O)C1=NC=CC=N1 FUXJMHXHGDAHPD-UHFFFAOYSA-N 0.000 abstract description 46
150000003839 salts Chemical class 0.000 abstract description 19
230000003266 anti-allergic effect Effects 0.000 abstract description 17
239000003814 drug Substances 0.000 abstract description 13
230000002579 anti-swelling effect Effects 0.000 abstract 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 196
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 118
-1 5-tetrazolyl Chemical group 0.000 description 112
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 100
239000011541 reaction mixture Substances 0.000 description 77
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 72
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 68
ZFCHNZDUMIOWFV-UHFFFAOYSA-N pyrimidine-2-carboxylic acid Chemical class OC(=O)C1=NC=CC=N1 ZFCHNZDUMIOWFV-UHFFFAOYSA-N 0.000 description 63
239000000047 product Substances 0.000 description 61
239000000243 solution Substances 0.000 description 59
ZFCHNZDUMIOWFV-UHFFFAOYSA-M pyrimidine-2-carboxylate Chemical compound [O-]C(=O)C1=NC=CC=N1 ZFCHNZDUMIOWFV-UHFFFAOYSA-M 0.000 description 58
239000012043 crude product Substances 0.000 description 57
238000001914 filtration Methods 0.000 description 50
238000001953 recrystallisation Methods 0.000 description 50
238000004458 analytical method Methods 0.000 description 46
239000002253 acid Substances 0.000 description 39
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 38
238000006243 chemical reaction Methods 0.000 description 35
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 33
239000007789 gas Substances 0.000 description 32
239000007787 solid Substances 0.000 description 32
230000000694 effects Effects 0.000 description 30
NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 28
UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 28
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 27
239000000203 mixture Substances 0.000 description 25
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 24
239000003921 oil Substances 0.000 description 24
235000019198 oils Nutrition 0.000 description 24
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 23
LTMHNWPUDSTBKD-UHFFFAOYSA-N diethyl 2-(ethoxymethylidene)propanedioate Chemical compound CCOC=C(C(=O)OCC)C(=O)OCC LTMHNWPUDSTBKD-UHFFFAOYSA-N 0.000 description 23
239000000741 silica gel Substances 0.000 description 23
229910002027 silica gel Inorganic materials 0.000 description 23
238000012360 testing method Methods 0.000 description 23
208000025865 Ulcer Diseases 0.000 description 22
239000004480 active ingredient Substances 0.000 description 22
239000002609 medium Substances 0.000 description 22
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 21
238000012546 transfer Methods 0.000 description 21
241000700159 Rattus Species 0.000 description 19
239000002904 solvent Substances 0.000 description 19
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
150000007513 acids Chemical class 0.000 description 18
231100000397 ulcer Toxicity 0.000 description 18
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 17
239000003480 eluent Substances 0.000 description 17
238000010992 reflux Methods 0.000 description 17
MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical compound C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 description 15
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
241001465754 Metazoa Species 0.000 description 15
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 14
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 13
239000002775 capsule Substances 0.000 description 13
238000004809 thin layer chromatography Methods 0.000 description 13
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 12
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 12
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
150000001408 amides Chemical class 0.000 description 12
229940079593 drug Drugs 0.000 description 12
239000000543 intermediate Substances 0.000 description 12
150000002500 ions Chemical class 0.000 description 12
238000007363 ring formation reaction Methods 0.000 description 12
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 11
230000015572 biosynthetic process Effects 0.000 description 11
239000003795 chemical substances by application Substances 0.000 description 11
150000002148 esters Chemical class 0.000 description 11
239000003826 tablet Substances 0.000 description 11
206010020751 Hypersensitivity Diseases 0.000 description 10
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 10
239000011734 sodium Substances 0.000 description 10
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
238000001816 cooling Methods 0.000 description 9
238000004090 dissolution Methods 0.000 description 9
230000005764 inhibitory process Effects 0.000 description 9
229910052708 sodium Inorganic materials 0.000 description 9
159000000000 sodium salts Chemical class 0.000 description 9
210000002784 stomach Anatomy 0.000 description 9
JVSMPWHQUPKRNV-UHFFFAOYSA-N 2h-tetrazol-5-amine;hydrate Chemical compound O.NC=1N=NNN=1 JVSMPWHQUPKRNV-UHFFFAOYSA-N 0.000 description 8
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 8
208000026935 allergic disease Diseases 0.000 description 8
239000000908 ammonium hydroxide Substances 0.000 description 8
208000003455 anaphylaxis Diseases 0.000 description 8
239000000427 antigen Substances 0.000 description 8
102000036639 antigens Human genes 0.000 description 8
108091007433 antigens Proteins 0.000 description 8
229960000265 cromoglicic acid Drugs 0.000 description 8
VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 8
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 8
239000000725 suspension Substances 0.000 description 8
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 8
206010002198 Anaphylactic reaction Diseases 0.000 description 7
SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 7
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 7
FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 7
230000006378 damage Effects 0.000 description 7
238000001035 drying Methods 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
230000007815 allergy Effects 0.000 description 6
230000036783 anaphylactic response Effects 0.000 description 6
150000008064 anhydrides Chemical class 0.000 description 6
HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 6
238000009833 condensation Methods 0.000 description 6
230000005494 condensation Effects 0.000 description 6
238000005755 formation reaction Methods 0.000 description 6
239000008103 glucose Substances 0.000 description 6
229960001340 histamine Drugs 0.000 description 6
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 6
238000003786 synthesis reaction Methods 0.000 description 6
238000011282 treatment Methods 0.000 description 6
238000001665 trituration Methods 0.000 description 6
RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical class NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 description 5
241000282472 Canis lupus familiaris Species 0.000 description 5
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 5
150000001412 amines Chemical class 0.000 description 5
230000000767 anti-ulcer Effects 0.000 description 5
238000003556 assay Methods 0.000 description 5
150000007942 carboxylates Chemical class 0.000 description 5
230000008878 coupling Effects 0.000 description 5
238000010168 coupling process Methods 0.000 description 5
238000005859 coupling reaction Methods 0.000 description 5
239000012442 inert solvent Substances 0.000 description 5
239000002207 metabolite Substances 0.000 description 5
239000012452 mother liquor Substances 0.000 description 5
239000002002 slurry Substances 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
GUABFMPMKJGSBQ-UHFFFAOYSA-N 5-methyl-1,3-thiazol-2-amine Chemical compound CC1=CN=C(N)S1 GUABFMPMKJGSBQ-UHFFFAOYSA-N 0.000 description 4
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
208000007107 Stomach Ulcer Diseases 0.000 description 4
230000000172 allergic effect Effects 0.000 description 4
239000000043 antiallergic agent Substances 0.000 description 4
239000003699 antiulcer agent Substances 0.000 description 4
239000008346 aqueous phase Substances 0.000 description 4
208000006673 asthma Diseases 0.000 description 4
208000010668 atopic eczema Diseases 0.000 description 4
150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 4
USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 4
231100000673 dose–response relationship Toxicity 0.000 description 4
125000004494 ethyl ester group Chemical group 0.000 description 4
239000012458 free base Substances 0.000 description 4
230000007062 hydrolysis Effects 0.000 description 4
238000006460 hydrolysis reaction Methods 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
230000003993 interaction Effects 0.000 description 4
239000008101 lactose Substances 0.000 description 4
235000019359 magnesium stearate Nutrition 0.000 description 4
239000000463 material Substances 0.000 description 4
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
239000002244 precipitate Substances 0.000 description 4
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
238000005406 washing Methods 0.000 description 4
RELMFMZEBKVZJC-UHFFFAOYSA-N 1,2,3-trichlorobenzene Chemical compound ClC1=CC=CC(Cl)=C1Cl RELMFMZEBKVZJC-UHFFFAOYSA-N 0.000 description 3
SIHBOLQMULXEHS-UHFFFAOYSA-N 1-chloro-1,1,2,2,2-pentafluoroethane;1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(F)C(F)(F)Cl.FC(F)(Cl)C(F)(F)Cl SIHBOLQMULXEHS-UHFFFAOYSA-N 0.000 description 3
ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 3
UZWADJYISZVARR-UHFFFAOYSA-N 4-butan-2-yl-1,3-thiazol-2-amine Chemical compound CCC(C)C1=CSC(N)=N1 UZWADJYISZVARR-UHFFFAOYSA-N 0.000 description 3
HNOGSSUZDLBROJ-UHFFFAOYSA-N 5-ethyl-1,3-thiazol-2-amine Chemical compound CCC1=CN=C(N)S1 HNOGSSUZDLBROJ-UHFFFAOYSA-N 0.000 description 3
CDUYCVWBLGEWSY-UHFFFAOYSA-N 5h-[1,3]thiazolo[3,2-a]pyrimidine Chemical compound C1C=CN=C2SC=CN12 CDUYCVWBLGEWSY-UHFFFAOYSA-N 0.000 description 3
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 3
RZZPDXZPRHQOCG-OJAKKHQRSA-O CDP-choline(1+) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-O 0.000 description 3
206010017865 Gastritis erosive Diseases 0.000 description 3
241000282412 Homo Species 0.000 description 3
108060003951 Immunoglobulin Proteins 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 3
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
239000000739 antihistaminic agent Substances 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 3
125000002091 cationic group Chemical group 0.000 description 3
230000001882 diuretic effect Effects 0.000 description 3
210000002216 heart Anatomy 0.000 description 3
102000018358 immunoglobulin Human genes 0.000 description 3
239000011159 matrix material Substances 0.000 description 3
230000036470 plasma concentration Effects 0.000 description 3
229910052700 potassium Inorganic materials 0.000 description 3
239000011591 potassium Substances 0.000 description 3
230000003389 potentiating effect Effects 0.000 description 3
239000000843 powder Substances 0.000 description 3
239000003380 propellant Substances 0.000 description 3
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
150000003180 prostaglandins Chemical class 0.000 description 3
238000000746 purification Methods 0.000 description 3
239000012264 purified product Substances 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
239000007858 starting material Substances 0.000 description 3
238000003756 stirring Methods 0.000 description 3
239000000126 substance Substances 0.000 description 3
YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
210000002700 urine Anatomy 0.000 description 3
HGBOYTHUEUWSSQ-UHFFFAOYSA-N valeric aldehyde Natural products CCCCC=O HGBOYTHUEUWSSQ-UHFFFAOYSA-N 0.000 description 3
KVNYFPKFSJIPBJ-UHFFFAOYSA-N 1,2-diethylbenzene Chemical compound CCC1=CC=CC=C1CC KVNYFPKFSJIPBJ-UHFFFAOYSA-N 0.000 description 2
PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 2
MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
ZBWHAEPVTLBSAG-UHFFFAOYSA-N 2-bromo-4-phenylcyclohexan-1-one Chemical compound C1CC(=O)C(Br)CC1C1=CC=CC=C1 ZBWHAEPVTLBSAG-UHFFFAOYSA-N 0.000 description 2
YGHRJJRRZDOVPD-UHFFFAOYSA-N 3-methylbutanal Chemical compound CC(C)CC=O YGHRJJRRZDOVPD-UHFFFAOYSA-N 0.000 description 2
FTOLLOHEFVCRJW-UHFFFAOYSA-N 4,5-di(propan-2-yl)-1,3-thiazol-2-amine Chemical compound CC(C)C=1N=C(N)SC=1C(C)C FTOLLOHEFVCRJW-UHFFFAOYSA-N 0.000 description 2
XMXLBDNVSIHRRA-UHFFFAOYSA-N 4,5-dimethyl-1,3-thiazol-2-amine Chemical compound CC=1N=C(N)SC=1C XMXLBDNVSIHRRA-UHFFFAOYSA-N 0.000 description 2
OUQMXTJYCAJLGO-UHFFFAOYSA-N 4-methyl-1,3-thiazol-2-amine Chemical compound CC1=CSC(N)=N1 OUQMXTJYCAJLGO-UHFFFAOYSA-N 0.000 description 2
DYWUOAQIROXLHV-UHFFFAOYSA-N 4-pentyl-1,3-thiazol-2-amine Chemical compound CCCCCC1=CSC(N)=N1 DYWUOAQIROXLHV-UHFFFAOYSA-N 0.000 description 2
LGPVXXJBWWYOSL-UHFFFAOYSA-N 4-propan-2-yl-1,3-thiazol-2-amine Chemical compound CC(C)C1=CSC(N)=N1 LGPVXXJBWWYOSL-UHFFFAOYSA-N 0.000 description 2
QMHIMXFNBOYPND-UHFFFAOYSA-N 4MTO Natural products CC1=CSC=N1 QMHIMXFNBOYPND-UHFFFAOYSA-N 0.000 description 2
AYNGEGJQFSDMCG-UHFFFAOYSA-N 5-pentyl-1,3-thiazol-2-amine Chemical compound CCCCCC1=CN=C(N)S1 AYNGEGJQFSDMCG-UHFFFAOYSA-N 0.000 description 2
MENMPXBUKLPJKR-UHFFFAOYSA-N 5-propan-2-yl-1,3-thiazol-2-amine Chemical compound CC(C)C1=CN=C(N)S1 MENMPXBUKLPJKR-UHFFFAOYSA-N 0.000 description 2
WURBKTNKFMMSGZ-UHFFFAOYSA-N 5-propyl-1,3-thiazol-2-amine Chemical compound CCCC1=CN=C(N)S1 WURBKTNKFMMSGZ-UHFFFAOYSA-N 0.000 description 2
206010002091 Anaesthesia Diseases 0.000 description 2
206010003497 Asphyxia Diseases 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 2
206010006482 Bronchospasm Diseases 0.000 description 2
BQENDLAVTKRQMS-SBBGFIFASA-L Carbenoxolone sodium Chemical compound [Na+].[Na+].C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C([O-])=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](OC(=O)CCC([O-])=O)C1(C)C BQENDLAVTKRQMS-SBBGFIFASA-L 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
235000019739 Dicalciumphosphate Nutrition 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
235000019759 Maize starch Nutrition 0.000 description 2
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
HGCZYCYBWYFIKJ-UHFFFAOYSA-N O.O.O.N1=C(N=CC=C1)C(=O)N Chemical compound O.O.O.N1=C(N=CC=C1)C(=O)N HGCZYCYBWYFIKJ-UHFFFAOYSA-N 0.000 description 2
108010058846 Ovalbumin Proteins 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
208000037656 Respiratory Sounds Diseases 0.000 description 2
206010039085 Rhinitis allergic Diseases 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
206010047924 Wheezing Diseases 0.000 description 2
210000001015 abdomen Anatomy 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
239000013543 active substance Substances 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
201000009961 allergic asthma Diseases 0.000 description 2
201000010105 allergic rhinitis Diseases 0.000 description 2
230000037005 anaesthesia Effects 0.000 description 2
230000002052 anaphylactic effect Effects 0.000 description 2
230000001387 anti-histamine Effects 0.000 description 2
230000001262 anti-secretory effect Effects 0.000 description 2
230000000794 anti-serotonin Effects 0.000 description 2
239000003420 antiserotonin agent Substances 0.000 description 2
239000007900 aqueous suspension Substances 0.000 description 2
239000002585 base Substances 0.000 description 2
230000008901 benefit Effects 0.000 description 2
239000004305 biphenyl Substances 0.000 description 2
235000010290 biphenyl Nutrition 0.000 description 2
125000006267 biphenyl group Chemical group 0.000 description 2
230000037396 body weight Effects 0.000 description 2
229940124630 bronchodilator Drugs 0.000 description 2
229910000019 calcium carbonate Inorganic materials 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
229960002252 carbenoxolone sodium Drugs 0.000 description 2
150000001718 carbodiimides Chemical class 0.000 description 2
239000000969 carrier Substances 0.000 description 2
231100000244 chromosomal damage Toxicity 0.000 description 2
229960001380 cimetidine Drugs 0.000 description 2
CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 2
230000001186 cumulative effect Effects 0.000 description 2
NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 2
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 2
229940038472 dicalcium phosphate Drugs 0.000 description 2
229910000390 dicalcium phosphate Inorganic materials 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
210000003238 esophagus Anatomy 0.000 description 2
RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 2
SHZIWNPUGXLXDT-UHFFFAOYSA-N ethyl hexanoate Chemical compound CCCCCC(=O)OCC SHZIWNPUGXLXDT-UHFFFAOYSA-N 0.000 description 2
239000008098 formaldehyde solution Substances 0.000 description 2
230000002496 gastric effect Effects 0.000 description 2
201000005917 gastric ulcer Diseases 0.000 description 2
230000035876 healing Effects 0.000 description 2
239000011551 heat transfer agent Substances 0.000 description 2
FXHGMKSSBGDXIY-UHFFFAOYSA-N heptanal Chemical compound CCCCCCC=O FXHGMKSSBGDXIY-UHFFFAOYSA-N 0.000 description 2
229910000042 hydrogen bromide Inorganic materials 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
230000000521 hyperimmunizing effect Effects 0.000 description 2
238000003018 immunoassay Methods 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
239000012535 impurity Substances 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
238000002955 isolation Methods 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
238000002156 mixing Methods 0.000 description 2
239000006199 nebulizer Substances 0.000 description 2
238000006386 neutralization reaction Methods 0.000 description 2
229940094443 oxytocics prostaglandins Drugs 0.000 description 2
231100000915 pathological change Toxicity 0.000 description 2
230000036285 pathological change Effects 0.000 description 2
230000035699 permeability Effects 0.000 description 2
239000003208 petroleum Substances 0.000 description 2
239000012071 phase Substances 0.000 description 2
ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
229910000027 potassium carbonate Inorganic materials 0.000 description 2
239000002243 precursor Substances 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
230000035484 reaction time Effects 0.000 description 2
239000012048 reactive intermediate Substances 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
238000006748 scratching Methods 0.000 description 2
230000002393 scratching effect Effects 0.000 description 2
229940076279 serotonin Drugs 0.000 description 2
239000012265 solid product Substances 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
150000003557 thiazoles Chemical class 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
230000036269 ulceration Effects 0.000 description 2
238000005303 weighing Methods 0.000 description 2
230000004580 weight loss Effects 0.000 description 2
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
229930182837 (R)-adrenaline Natural products 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
NNTPEAXKKUPBHQ-UHFFFAOYSA-N 1-bromo-3-methylbutan-2-one Chemical compound CC(C)C(=O)CBr NNTPEAXKKUPBHQ-UHFFFAOYSA-N 0.000 description 1
PNYNRQLIDYPZBP-UHFFFAOYSA-N 1-bromo-3-methylpentan-2-one Chemical compound CCC(C)C(=O)CBr PNYNRQLIDYPZBP-UHFFFAOYSA-N 0.000 description 1
RCTWZRNOJCMIDN-UHFFFAOYSA-N 1-bromoheptan-2-one Chemical compound CCCCCC(=O)CBr RCTWZRNOJCMIDN-UHFFFAOYSA-N 0.000 description 1
ZJLOTYVKNLWYNJ-UHFFFAOYSA-N 1-ethyl-5-methyl-2h-tetrazol-3-amine Chemical compound CCN1NN(N)N=C1C ZJLOTYVKNLWYNJ-UHFFFAOYSA-N 0.000 description 1
OKRROXQXGNEUSS-UHFFFAOYSA-N 1h-imidazol-1-ium-1-carboxylate Chemical compound OC(=O)N1C=CN=C1 OKRROXQXGNEUSS-UHFFFAOYSA-N 0.000 description 1
ALUQMCBDQKDRAK-UHFFFAOYSA-N 2,3,3a,4-tetrahydro-1,3-benzothiazole Chemical compound C1C=CC=C2SCNC21 ALUQMCBDQKDRAK-UHFFFAOYSA-N 0.000 description 1
UKCDSQTVXRZOQT-UHFFFAOYSA-N 2,4-diethyl-1,3-thiazole;hydrochloride Chemical compound Cl.CCC1=CSC(CC)=N1 UKCDSQTVXRZOQT-UHFFFAOYSA-N 0.000 description 1
GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 1
CYXIKYKBLDZZNW-UHFFFAOYSA-N 2-Chloro-1,1,1-trifluoroethane Chemical compound FC(F)(F)CCl CYXIKYKBLDZZNW-UHFFFAOYSA-N 0.000 description 1
XTNIIFLVRBKXKS-UHFFFAOYSA-N 2-bromo-3,5-dimethylcyclohexan-1-one Chemical compound CC1CC(C)C(Br)C(=O)C1 XTNIIFLVRBKXKS-UHFFFAOYSA-N 0.000 description 1
STOIGSXOHCYRHB-UHFFFAOYSA-N 2-bromo-3-phenylcyclopentan-1-one Chemical compound C1CC(=O)C(Br)C1C1=CC=CC=C1 STOIGSXOHCYRHB-UHFFFAOYSA-N 0.000 description 1
RDUXIRQZBLFPOW-UHFFFAOYSA-N 2-bromo-4,4-dimethylcyclohexan-1-one Chemical compound CC1(C)CCC(=O)C(Br)C1 RDUXIRQZBLFPOW-UHFFFAOYSA-N 0.000 description 1
ZGKHYOAPWMMURT-UHFFFAOYSA-N 2-bromo-4-methylcyclohexan-1-one Chemical compound CC1CCC(=O)C(Br)C1 ZGKHYOAPWMMURT-UHFFFAOYSA-N 0.000 description 1
AUOFBDGRGCUSBU-UHFFFAOYSA-N 2-bromo-5-methylcyclooctan-1-one Chemical compound CC1CCCC(=O)C(Br)CC1 AUOFBDGRGCUSBU-UHFFFAOYSA-N 0.000 description 1
VUDTYIUNUSPULX-UHFFFAOYSA-N 2-bromopentan-3-one Chemical compound CCC(=O)C(C)Br VUDTYIUNUSPULX-UHFFFAOYSA-N 0.000 description 1
SDSZGDVXUFWFAA-UHFFFAOYSA-N 2-chlorocycloheptan-1-one Chemical compound ClC1CCCCCC1=O SDSZGDVXUFWFAA-UHFFFAOYSA-N 0.000 description 1
CFMZSMGAMPBRBE-UHFFFAOYSA-N 2-hydroxyisoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(O)C(=O)C2=C1 CFMZSMGAMPBRBE-UHFFFAOYSA-N 0.000 description 1
VZWOXDYRBDIHMA-UHFFFAOYSA-N 2-methyl-1,3-thiazole Chemical compound CC1=NC=CS1 VZWOXDYRBDIHMA-UHFFFAOYSA-N 0.000 description 1
LPCQBTAOTIZGAE-UHFFFAOYSA-N 2h-pyrimidine-1-carboxamide Chemical compound NC(=O)N1CN=CC=C1 LPCQBTAOTIZGAE-UHFFFAOYSA-N 0.000 description 1
MWOOKDULMBMMPN-UHFFFAOYSA-N 3-(2-ethyl-1,2-oxazol-2-ium-5-yl)benzenesulfonate Chemical compound O1[N+](CC)=CC=C1C1=CC=CC(S([O-])(=O)=O)=C1 MWOOKDULMBMMPN-UHFFFAOYSA-N 0.000 description 1
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
SFKVBRLKXVRUQW-UHFFFAOYSA-N 3-bromoheptan-4-one Chemical compound CCCC(=O)C(Br)CC SFKVBRLKXVRUQW-UHFFFAOYSA-N 0.000 description 1
RBHQXHJBVLYVIF-UHFFFAOYSA-N 4,5-diethyl-1,3-thiazole;hydrochloride Chemical compound Cl.CCC=1N=CSC=1CC RBHQXHJBVLYVIF-UHFFFAOYSA-N 0.000 description 1
SVZQNMALBABBQP-UHFFFAOYSA-N 4-bromo-2,5-dimethylhexan-3-one Chemical compound CC(C)C(Br)C(=O)C(C)C SVZQNMALBABBQP-UHFFFAOYSA-N 0.000 description 1
JLRAWVOPMUYZEP-UHFFFAOYSA-N 4-chlorohexan-3-one Chemical compound CCC(Cl)C(=O)CC JLRAWVOPMUYZEP-UHFFFAOYSA-N 0.000 description 1
JJDSGHBAXFTEHZ-UHFFFAOYSA-N 4-ethyl-1,3-thiazol-2-amine Chemical compound CCC1=CSC(N)=N1 JJDSGHBAXFTEHZ-UHFFFAOYSA-N 0.000 description 1
XPDXICVHAINXCZ-UHFFFAOYSA-N 4-ethyl-5-methyl-1,3-thiazol-2-amine Chemical compound CCC=1N=C(N)SC=1C XPDXICVHAINXCZ-UHFFFAOYSA-N 0.000 description 1
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
JTJGLQLRUUWMOZ-UHFFFAOYSA-N 4-propan-2-yl-1,3-thiazol-2-amine;hydrobromide Chemical compound Br.CC(C)C1=CSC(N)=N1 JTJGLQLRUUWMOZ-UHFFFAOYSA-N 0.000 description 1
XPQULTFBJPGINB-UHFFFAOYSA-N 5-Ethyl-4-methylthiazole Chemical compound CCC=1SC=NC=1C XPQULTFBJPGINB-UHFFFAOYSA-N 0.000 description 1
GJEROFWFRBOYBZ-UHFFFAOYSA-N 5-bromo-2,2,4-trimethylcyclopentan-1-one Chemical compound CC1CC(C)(C)C(=O)C1Br GJEROFWFRBOYBZ-UHFFFAOYSA-N 0.000 description 1
JGWJSBCQVNZWSA-UHFFFAOYSA-N 5-ethyl-4-propyl-1,3-thiazol-2-amine Chemical compound CCCC=1N=C(N)SC=1CC JGWJSBCQVNZWSA-UHFFFAOYSA-N 0.000 description 1
RLYUNPNLXMSXAX-UHFFFAOYSA-N 5-methylthiazole Chemical compound CC1=CN=CS1 RLYUNPNLXMSXAX-UHFFFAOYSA-N 0.000 description 1
RGPMCMYHWAEMSM-UHFFFAOYSA-N 5-propyl-1,3-thiazole Chemical compound CCCC1=CN=CS1 RGPMCMYHWAEMSM-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
229930003347 Atropine Natural products 0.000 description 1
208000009079 Bronchial Spasm Diseases 0.000 description 1
208000014181 Bronchial disease Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
206010007559 Cardiac failure congestive Diseases 0.000 description 1
206010048964 Carotid artery occlusion Diseases 0.000 description 1
241000700198 Cavia Species 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
101150065749 Churc1 gene Proteins 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
WFZKRNIMSVDNBU-UHFFFAOYSA-N Creatinine sulfate mixture with serotonin Chemical compound [O-]S([O-])(=O)=O.C[NH+]1CC(=O)N=C1N.C1=C(O)C=C2C(CC[NH3+])=CNC2=C1 WFZKRNIMSVDNBU-UHFFFAOYSA-N 0.000 description 1
206010012438 Dermatitis atopic Diseases 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
208000004262 Food Hypersensitivity Diseases 0.000 description 1
206010016946 Food allergy Diseases 0.000 description 1
101000693916 Gallus gallus Albumin Proteins 0.000 description 1
MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
229940122236 Histamine receptor antagonist Drugs 0.000 description 1
RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
208000001953 Hypotension Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
208000007101 Muscle Cramp Diseases 0.000 description 1
208000010428 Muscle Weakness Diseases 0.000 description 1
206010028372 Muscular weakness Diseases 0.000 description 1
JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 1
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
206010028735 Nasal congestion Diseases 0.000 description 1
235000019502 Orange oil Nutrition 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
108010079943 Pentagastrin Proteins 0.000 description 1
YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
229920005372 Plexiglas® Polymers 0.000 description 1
102100038239 Protein Churchill Human genes 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
208000036071 Rhinorrhea Diseases 0.000 description 1
206010039101 Rhinorrhoea Diseases 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
208000005392 Spasm Diseases 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
239000000150 Sympathomimetic Substances 0.000 description 1
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
102000003929 Transaminases Human genes 0.000 description 1
108090000340 Transaminases Proteins 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
210000000683 abdominal cavity Anatomy 0.000 description 1
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
229960004373 acetylcholine Drugs 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
238000005903 acid hydrolysis reaction Methods 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000004703 alkoxides Chemical class 0.000 description 1
208000030961 allergic reaction Diseases 0.000 description 1
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000001088 anti-asthma Effects 0.000 description 1
230000001078 anti-cholinergic effect Effects 0.000 description 1
230000002686 anti-diuretic effect Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
239000000924 antiasthmatic agent Substances 0.000 description 1
239000003160 antidiuretic agent Substances 0.000 description 1
229940124538 antidiuretic agent Drugs 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
201000008937 atopic dermatitis Diseases 0.000 description 1
RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
229960000396 atropine Drugs 0.000 description 1
238000011001 backwashing Methods 0.000 description 1
239000003637 basic solution Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical class C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
210000000621 bronchi Anatomy 0.000 description 1
230000007885 bronchoconstriction Effects 0.000 description 1
239000000168 bronchodilator agent Substances 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
230000004856 capillary permeability Effects 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003610 charcoal Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
AOGYCOYQMAVAFD-UHFFFAOYSA-N chlorocarbonic acid Chemical class OC(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-N 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
239000007859 condensation product Substances 0.000 description 1
235000009508 confectionery Nutrition 0.000 description 1
208000027744 congestion Diseases 0.000 description 1
239000000470 constituent Substances 0.000 description 1
230000008602 contraction Effects 0.000 description 1
230000001595 contractor effect Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
230000000911 decarboxylating effect Effects 0.000 description 1
238000006114 decarboxylation reaction Methods 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
125000000950 dibromo group Chemical group Br* 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000000378 dietary effect Effects 0.000 description 1
RCELBOUJNVFMCB-UHFFFAOYSA-N diethyl 2-[(2-aminophenyl)methyl]propanedioate Chemical compound CCOC(=O)C(C(=O)OCC)CC1=CC=CC=C1N RCELBOUJNVFMCB-UHFFFAOYSA-N 0.000 description 1
ZZTSQZQUWBFTAT-UHFFFAOYSA-N diethylcyanamide Chemical compound CCN(CC)C#N ZZTSQZQUWBFTAT-UHFFFAOYSA-N 0.000 description 1
210000002249 digestive system Anatomy 0.000 description 1
GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
VLQFGQDSWBZCHS-UHFFFAOYSA-N dipropan-2-yl 2-(ethoxymethylidene)propanedioate Chemical compound CCOC=C(C(=O)OC(C)C)C(=O)OC(C)C VLQFGQDSWBZCHS-UHFFFAOYSA-N 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000004821 distillation Methods 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
208000000718 duodenal ulcer Diseases 0.000 description 1
238000004043 dyeing Methods 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
229960003720 enoxolone Drugs 0.000 description 1
229960005139 epinephrine Drugs 0.000 description 1
239000002024 ethyl acetate extract Substances 0.000 description 1
WMYNMYVRWWCRPS-UHFFFAOYSA-N ethynoxyethane Chemical group CCOC#C WMYNMYVRWWCRPS-UHFFFAOYSA-N 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
230000029142 excretion Effects 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000011049 filling Methods 0.000 description 1
238000005187 foaming Methods 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
210000004211 gastric acid Anatomy 0.000 description 1
230000027119 gastric acid secretion Effects 0.000 description 1
230000030136 gastric emptying Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
239000010931 gold Substances 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
229940046528 grass pollen Drugs 0.000 description 1
230000026030 halogenation Effects 0.000 description 1
238000005658 halogenation reaction Methods 0.000 description 1
229960004931 histamine dihydrochloride Drugs 0.000 description 1
PPZMYIBUHIPZOS-UHFFFAOYSA-N histamine dihydrochloride Chemical compound Cl.Cl.NCCC1=CN=CN1 PPZMYIBUHIPZOS-UHFFFAOYSA-N 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
150000002431 hydrogen Chemical class 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
230000035874 hyperreactivity Effects 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
230000036543 hypotension Effects 0.000 description 1
210000003405 ileum Anatomy 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000000984 immunochemical effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
229940060367 inert ingredients Drugs 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
239000002555 ionophore Substances 0.000 description 1
230000000236 ionophoric effect Effects 0.000 description 1
150000002537 isoquinolines Chemical class 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
230000003902 lesion Effects 0.000 description 1
231100000225 lethality Toxicity 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229940050906 magnesium chloride hexahydrate Drugs 0.000 description 1
DHRRIBDTHFBPNG-UHFFFAOYSA-L magnesium dichloride hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-] DHRRIBDTHFBPNG-UHFFFAOYSA-L 0.000 description 1
239000000391 magnesium silicate Substances 0.000 description 1
229940091250 magnesium supplement Drugs 0.000 description 1
229940099273 magnesium trisilicate Drugs 0.000 description 1
229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
235000019793 magnesium trisilicate Nutrition 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000000155 melt Substances 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
230000007886 mutagenicity Effects 0.000 description 1
231100000299 mutagenicity Toxicity 0.000 description 1
230000035772 mutation Effects 0.000 description 1
UDGSVBYJWHOHNN-UHFFFAOYSA-N n',n'-diethylethane-1,2-diamine Chemical compound CCN(CC)CCN UDGSVBYJWHOHNN-UHFFFAOYSA-N 0.000 description 1
YHHNXMTTWKAUEQ-UHFFFAOYSA-N n-(4-methylphenyl)-2,2-diphenylethenimine Chemical compound C1=CC(C)=CC=C1N=C=C(C=1C=CC=CC=1)C1=CC=CC=C1 YHHNXMTTWKAUEQ-UHFFFAOYSA-N 0.000 description 1
LKPFBGKZCCBZDK-UHFFFAOYSA-N n-hydroxypiperidine Chemical compound ON1CCCCC1 LKPFBGKZCCBZDK-UHFFFAOYSA-N 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
235000020925 non fasting Nutrition 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
229940126701 oral medication Drugs 0.000 description 1
239000010502 orange oil Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
230000020477 pH reduction Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
235000010603 pastilles Nutrition 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
ANRIQLNBZQLTFV-DZUOILHNSA-N pentagastrin Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1[C]2C=CC=CC2=NC=1)NC(=O)CCNC(=O)OC(C)(C)C)CCSC)C(N)=O)C1=CC=CC=C1 ANRIQLNBZQLTFV-DZUOILHNSA-N 0.000 description 1
229960000444 pentagastrin Drugs 0.000 description 1
125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
239000008024 pharmaceutical diluent Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 1
229960002895 phenylbutazone Drugs 0.000 description 1
VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000004926 polymethyl methacrylate Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
229910001414 potassium ion Inorganic materials 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
230000001376 precipitating effect Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
239000013014 purified material Substances 0.000 description 1
210000001187 pylorus Anatomy 0.000 description 1
VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
229940107700 pyruvic acid Drugs 0.000 description 1
LOAUVZALPPNFOQ-UHFFFAOYSA-N quinaldic acid Chemical compound C1=CC=CC2=NC(C(=O)O)=CC=C21 LOAUVZALPPNFOQ-UHFFFAOYSA-N 0.000 description 1
ZEXKKIXCRDTKBF-UHFFFAOYSA-N quinoline-2-carboxamide Chemical class C1=CC=CC2=NC(C(=O)N)=CC=C21 ZEXKKIXCRDTKBF-UHFFFAOYSA-N 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
238000011084 recovery Methods 0.000 description 1
238000001226 reprecipitation Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
230000000452 restraining effect Effects 0.000 description 1
206010039083 rhinitis Diseases 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000001932 seasonal effect Effects 0.000 description 1
239000012056 semi-solid material Substances 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
238000010898 silica gel chromatography Methods 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
229910001415 sodium ion Inorganic materials 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
241000894007 species Species 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
239000000021 stimulant Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
238000010998 test method Methods 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
125000003831 tetrazolyl group Chemical group 0.000 description 1
229960000278 theophylline Drugs 0.000 description 1
229940126585 therapeutic drug Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
150000007979 thiazole derivatives Chemical class 0.000 description 1
RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
150000004684 trihydrates Chemical class 0.000 description 1
230000008673 vomiting Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/40—Unsubstituted amino or imino radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Immunology (AREA)
Diabetes (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Thiazole And Isothizaole Compounds (AREA)

DD80225391A 1979-11-23 1980-11-21 Verfahren zur herstellung von 1x oxo-1h-thiazolo-[3,2-a]pyrimidin-carboxamiden u.deren zwischenstufen DD154608A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US9663179A	1979-11-23	1979-11-23

Publications (1)

Publication Number	Publication Date
DD154608A5 true DD154608A5 (de)	1982-04-07

Family

ID=22258306

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD80225391A DD154608A5 (de)	1979-11-23	1980-11-21	Verfahren zur herstellung von 1x oxo-1h-thiazolo-[3,2-a]pyrimidin-carboxamiden u.deren zwischenstufen

Country Status (35)

Country	Link
JP (1)	JPS5687586A (fr)
KR (1)	KR830004322A (fr)
AR (2)	AR228859A1 (fr)
AT (1)	AT380883B (fr)
AU (1)	AU520995B2 (fr)
BE (1)	BE886319A (fr)
CA (1)	CA1143731A (fr)
CH (1)	CH649299A5 (fr)
CS (1)	CS241476B2 (fr)
DD (1)	DD154608A5 (fr)
DE (2)	DE3050491C2 (fr)
DK (1)	DK151811C (fr)
EG (1)	EG14929A (fr)
ES (1)	ES497066A0 (fr)
FI (1)	FI67706C (fr)
FR (1)	FR2470132A1 (fr)
GB (1)	GB2063862B (fr)
GR (1)	GR72132B (fr)
GT (1)	GT198066458A (fr)
HU (1)	HU179091B (fr)
IE (1)	IE50404B1 (fr)
IL (1)	IL61535A (fr)
IN (1)	IN154926B (fr)
IT (1)	IT1209373B (fr)
LU (1)	LU82950A1 (fr)
NL (1)	NL182565C (fr)
NO (1)	NO803521L (fr)
NZ (1)	NZ195596A (fr)
PH (1)	PH16666A (fr)
PL (1)	PL132354B1 (fr)
PT (1)	PT72090B (fr)
SE (1)	SE448732B (fr)
SU (1)	SU1042620A3 (fr)
YU (1)	YU41953B (fr)
ZA (1)	ZA807293B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8300728D0 (en) *	1983-01-12	1983-02-16	Erba Farmitalia	Substituted carboxy-thiazolo / 3 2 - a / pyrimidine derivatives
US4457932A (en) *	1983-07-22	1984-07-03	Bristol-Myers Company	Anti-ulcer agents
GB8422916D0 (en) *	1984-09-11	1984-10-17	May & Baker Ltd	Compositions of matter
JP2690742B2 (ja) *	1987-03-30	1997-12-17	第一製薬株式会社	複素環アミン誘導体
NZ228447A (en) *	1988-03-28	1990-08-28	Janssen Pharmaceutica Nv	Cosmetic or pharmaceutical composition possessing serotonin antogonistic activity
TWI500623B (zh) *	2009-10-13	2015-09-21	Torrent Pharmaceuticals Ltd	新穎稠合噻唑及噁唑嘧啶酮

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1331059A (en)	1971-04-19	1973-09-19	Lilly Industries Ltd	Pyrimidotriazinone compounds
US4041163A (en) *	1976-03-29	1977-08-09	Pfizer Inc.	N-(5-Tetrazolyl)-4-oxo-4H-pyrimido(2,1-b)benzothiazole-3-carboxamide antiallergy agents
DE2810863A1 (de) *	1978-03-13	1979-09-27	Boehringer Mannheim Gmbh	1-oxo-1h-pyrimido eckige klammer auf 6,1-b eckige klammer zu benzthiazol-derivate und verfahren zu ihrer herstellung
US4223031A (en) *	1978-05-05	1980-09-16	Mead Johnson & Company	Azolopyrimidinones

1980
- 1980-09-30 DK DK413180A patent/DK151811C/da not_active IP Right Cessation
- 1980-10-15 IN IN760/DEL/80A patent/IN154926B/en unknown
- 1980-11-17 SU SU803212053A patent/SU1042620A3/ru active
- 1980-11-18 GB GB8036904A patent/GB2063862B/en not_active Expired
- 1980-11-18 HU HU80802755A patent/HU179091B/hu not_active IP Right Cessation
- 1980-11-18 AR AR283276A patent/AR228859A1/es active
- 1980-11-18 CS CS807820A patent/CS241476B2/cs unknown
- 1980-11-19 EG EG723/80A patent/EG14929A/xx active
- 1980-11-19 CH CH8567/80A patent/CH649299A5/fr not_active IP Right Cessation
- 1980-11-20 GR GR63413A patent/GR72132B/el unknown
- 1980-11-20 NZ NZ195596A patent/NZ195596A/en unknown
- 1980-11-20 YU YU2950/80A patent/YU41953B/xx unknown
- 1980-11-21 NL NLAANVRAGE8006362,A patent/NL182565C/xx not_active IP Right Cessation
- 1980-11-21 NO NO803521A patent/NO803521L/no unknown
- 1980-11-21 ZA ZA00807293A patent/ZA807293B/xx unknown
- 1980-11-21 CA CA000365258A patent/CA1143731A/fr not_active Expired
- 1980-11-21 PT PT72090A patent/PT72090B/pt not_active IP Right Cessation
- 1980-11-21 DD DD80225391A patent/DD154608A5/de not_active IP Right Cessation
- 1980-11-21 IL IL61535A patent/IL61535A/xx unknown
- 1980-11-21 IE IE2418/80A patent/IE50404B1/en unknown
- 1980-11-21 DE DE3050491A patent/DE3050491C2/de not_active Expired
- 1980-11-21 SE SE8008189A patent/SE448732B/sv not_active IP Right Cessation
- 1980-11-21 ES ES497066A patent/ES497066A0/es active Granted
- 1980-11-21 GT GT198066458A patent/GT198066458A/es unknown
- 1980-11-21 AT AT0570780A patent/AT380883B/de not_active IP Right Cessation
- 1980-11-21 AU AU64595/80A patent/AU520995B2/en not_active Ceased
- 1980-11-21 FR FR8024822A patent/FR2470132A1/fr active Granted
- 1980-11-21 JP JP16450280A patent/JPS5687586A/ja active Granted
- 1980-11-21 LU LU82950A patent/LU82950A1/fr unknown
- 1980-11-21 FI FI803628A patent/FI67706C/fi not_active IP Right Cessation
- 1980-11-21 IT IT8026176A patent/IT1209373B/it active
- 1980-11-21 PH PH24891A patent/PH16666A/en unknown
- 1980-11-21 DE DE3043979A patent/DE3043979C2/de not_active Expired
- 1980-11-22 KR KR1019800004474A patent/KR830004322A/ko not_active Ceased
- 1980-11-22 PL PL1980228008A patent/PL132354B1/pl unknown
- 1980-11-24 BE BE0/202915A patent/BE886319A/fr not_active IP Right Cessation
1982
- 1982-09-13 AR AR290628A patent/AR231296A1/es active

Also Published As

Publication number	Publication date
LU82950A1 (fr)	1981-06-04
PL132354B1 (en)	1985-02-28
NO803521L (no)	1981-05-25
NL182565C (nl)	1988-04-05
NZ195596A (en)	1984-05-31
FI67706C (fi)	1985-05-10
IL61535A (en)	1984-06-29
GB2063862B (en)	1983-06-22
ES8203363A1 (es)	1982-04-01
PH16666A (en)	1983-12-13
CS241476B2 (en)	1986-03-13
JPS617432B2 (fr)	1986-03-06
SU1042620A3 (ru)	1983-09-15
KR830004322A (ko)	1983-07-09
CH649299A5 (fr)	1985-05-15
AR231296A1 (es)	1984-10-31
PL228008A1 (fr)	1981-12-11
DE3050491C2 (de)	1985-10-10
IN154926B (fr)	1984-12-22
DK151811B (da)	1988-01-04
AT380883B (de)	1986-07-25
IL61535A0 (en)	1980-12-31
SE8008189L (sv)	1981-05-24
DE3043979C2 (de)	1986-08-21
YU41953B (en)	1988-02-29
AU520995B2 (en)	1982-03-11
PT72090A (en)	1980-12-01
GB2063862A (en)	1981-06-10
JPS5687586A (en)	1981-07-16
FI803628L (fi)	1981-05-24
CS782080A2 (en)	1985-06-13
CA1143731A (fr)	1983-03-29
DK413180A (da)	1981-05-24
AU6459580A (en)	1981-05-28
GR72132B (fr)	1983-09-19
FI67706B (fi)	1985-01-31
PT72090B (en)	1981-09-29
AR228859A1 (es)	1983-04-29
ATA570780A (de)	1985-12-15
DK151811C (da)	1988-06-06
DE3043979A1 (de)	1981-09-03
SE448732B (sv)	1987-03-16
NL8006362A (nl)	1981-06-16
GT198066458A (es)	1982-05-15
IE802418L (en)	1981-05-23
YU295080A (en)	1983-06-30
ZA807293B (en)	1981-12-30
NL182565B (nl)	1987-11-02
HU179091B (en)	1982-08-28
IE50404B1 (en)	1986-04-16
ES497066A0 (es)	1982-04-01
IT1209373B (it)	1989-07-16
FR2470132A1 (fr)	1981-05-29
FR2470132B1 (fr)	1983-07-29
EG14929A (en)	1989-01-30
IT8026176A0 (it)	1980-11-21
BE886319A (fr)	1981-05-25

Legal Events

Date	Code	Title	Description
1998-08-27	ENJ	Ceased due to non-payment of renewal fee

Publication	Publication Date	Title
EP0002482B1 (fr)	1981-01-07	1,1-Dioxydes de 4-hydroxy-2H-1,2-benzothiazine-3-carboxamides, leurs procedés de préparation et compositions pharmaceutiques les contenant
DE2740588A1 (de)	1978-03-16	Imidazo- eckige klammer auf 1,2-a eckige klammer zu -chinolin-2-carbon- saeuren und deren derivate sowie pharmazeutische zubereitungen, die diese verbindungen enthalten
HU188852B (en)	1986-05-28	Process for producing thiazolidine derivatives active against gastric ulcer and intestinal ulcer
CH641460A5 (de)	1984-02-29	Azolopyrimidinone und verwandte verbindungen.
EP0185909B1 (fr)	1990-02-21	Composés de 5-alkyl-1-phényl-2-pipérazinoalkylpyrazolin-3-one ainsi que procédés et produits intermédiaires pour leur préparation et médicaments comprenant ces composés
DE2634903A1 (de)	1977-02-17	Neue thienopyridinderivate und sie enthaltende arzneimittel
DE3043979A1 (de)	1981-09-03	Antiallergische und geschwuerwidrige 1-oxo-1h-thiazolo-(3,2-a) pyrimidin-2-carboxamide und deren zwischenstufen
DE2404050A1 (de)	1974-08-08	Neue heterocyclische vrbindungen und verfahren zu deren herstellung
DE2344611A1 (de)	1974-03-14	5-(substituierte phenoxy)-4-aminound -substituierte aminopyrimidine
US4423048A (en)	1983-12-27	Antiallergic and antiulcer 1-oxo-1H-thiazolo[3,2-a]pyrimidine-2-carboxamides and intermediates therefor
US4535081A (en)	1985-08-13	Antiallergic and antiulcer 1-oxo-1H-thiazolo[3,2-a]pyrimidine-2-carboxamides and intermediates therefor
DD219642A5 (de)	1985-03-13	Verfahren zur herstellung von bis-(piperazinyl- bzw. homopiperazinyl)alkanen
DE60207273T2 (de)	2006-07-20	Aminopyrrolverbindungen als entzündungshemmende Wirkstoffe
DE2630469C2 (de)	1982-04-08	6-Alkoxy-N-(5-tetrazolyl)-1-oxo-1H-pyrimido-[1,2-a] chinolin-2-carboxamide, Verfahren zu deren Herstellung und dieselben enthaltende antiallergisch wirksame pharmazeutische Zubereitungen
EP0276805B1 (fr)	1993-03-17	3-Phényl-7H-thiazolo[3,2-b][1,2,4]triazin-7-ones substituées, procédés pour leur préparation, médicaments les contenant et leur utilisation ainsi que quelques-uns des produits intermédiaires obtenus de la préparation desdits produits
DE2644121A1 (de)	1978-04-06	Neue pyridobenzodiazepinone, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
US4414388A (en)	1983-11-08	1-Oxo-1H-thiazolo[3,2-a]pyrimidine-2-carboxamides
DE3413875A1 (de)	1985-10-17	Benzothiazolderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltendes arzneimittel
CH639389A5 (de)	1983-11-15	2,5-dihydro-1,2-thiazino(5,6-b)indol-3-carboxamid-1,1-dioxide, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
DD283821A5 (de)	1990-10-24	Verfahren zur herstellung von mevalonolactonen mit einem pyrazolopyridin-ring
DE2452996A1 (de)	1976-05-20	Neue 4-hydroxy-2h-naphtho- eckige klammer auf 2,1-e eckige klammer zu -1,2thiazin-3-carboxamid-1,1-dioxide, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
FI71158B (fi)	1986-08-14	Foerfarande foer framstaellning av terapeutiskt anvaendbara 1-xo-1h-tiazolo/3,2-a/pyrimidin-2-karboxylsyror
DE3702757A1 (de)	1988-08-11	Neue imidazo- und triazolo-thiadiazine, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung, sowie einige bei der herstellung der genannten verbindungen gebildete zwischenprodukte
DE3400733A1 (de)	1984-07-12	Substituierte carboxy-thiazolo-(3,2-a)-pyrimidinderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zubereitungen
CH620217A5 (fr)	1980-11-14